JP6100692B2 - 睡眠の質改善剤 - Google Patents
睡眠の質改善剤 Download PDFInfo
- Publication number
- JP6100692B2 JP6100692B2 JP2013537583A JP2013537583A JP6100692B2 JP 6100692 B2 JP6100692 B2 JP 6100692B2 JP 2013537583 A JP2013537583 A JP 2013537583A JP 2013537583 A JP2013537583 A JP 2013537583A JP 6100692 B2 JP6100692 B2 JP 6100692B2
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- ash
- extract
- sleep quality
- improving agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003860 sleep quality Effects 0.000 title claims description 122
- 230000007958 sleep Effects 0.000 claims description 115
- 239000000284 extract Substances 0.000 claims description 107
- 235000008124 Picea excelsa Nutrition 0.000 claims description 56
- 230000008452 non REM sleep Effects 0.000 claims description 38
- 230000004622 sleep time Effects 0.000 claims description 38
- 239000004480 active ingredient Substances 0.000 claims description 30
- 206010041349 Somnolence Diseases 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 230000006872 improvement Effects 0.000 claims description 18
- 230000002618 waking effect Effects 0.000 claims description 18
- 230000004620 sleep latency Effects 0.000 claims description 12
- 230000008667 sleep stage Effects 0.000 claims description 10
- 241000896100 Larix sibirica Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 description 66
- 244000193463 Picea excelsa Species 0.000 description 54
- 230000000052 comparative effect Effects 0.000 description 46
- 239000000523 sample Substances 0.000 description 39
- 241000196324 Embryophyta Species 0.000 description 38
- 230000008859 change Effects 0.000 description 34
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 31
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 31
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 28
- 241000006351 Leucophyllum frutescens Species 0.000 description 26
- PADQINQHPQKXNL-LSDHHAIUSA-N (+)-dihydrokaempferol Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C=C1 PADQINQHPQKXNL-LSDHHAIUSA-N 0.000 description 23
- RAYJUFCFJUVJBB-UHFFFAOYSA-N dihydrokaempferol Natural products OC1Oc2c(O)cc(O)cc2C(=O)C1c3ccc(O)cc3 RAYJUFCFJUVJBB-UHFFFAOYSA-N 0.000 description 23
- 229940117954 naringenin Drugs 0.000 description 23
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 23
- 235000007625 naringenin Nutrition 0.000 description 23
- 239000003814 drug Substances 0.000 description 20
- 235000013305 food Nutrition 0.000 description 20
- 230000006399 behavior Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 208000032140 Sleepiness Diseases 0.000 description 15
- 230000037321 sleepiness Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 12
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 206010062519 Poor quality sleep Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- -1 for example Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 239000007901 soft capsule Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010014172 Factor V Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 108010000499 Thromboplastin Proteins 0.000 description 6
- 102000002262 Thromboplastin Human genes 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 244000181980 Fraxinus excelsior Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003326 hypnotic agent Substances 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 239000004129 EU approved improving agent Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241001536352 Fraxinus americana Species 0.000 description 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010029412 Nightmare Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241001536358 Fraxinus Species 0.000 description 1
- 241000537370 Fraxinus bungeana Species 0.000 description 1
- 241000565359 Fraxinus chinensis Species 0.000 description 1
- 241000565357 Fraxinus nigra Species 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 241000549534 Fraxinus paxiana Species 0.000 description 1
- 241000549547 Fraxinus sieboldiana Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 244000097202 Rathbunia alamosensis Species 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical group C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Description
〔2〕トネリコ属植物またはその抽出エキスを有効成分とする前記〔1〕に記載の睡眠の質改善剤。
〔3〕トネリコ属植物がセイヨウトネリコである前記〔1〕または〔2〕に記載の睡眠の質改善剤。
〔4〕トネリコ属植物の抽出エキスがセイヨウトネリコエキスである前記〔1〕または〔2〕に記載の睡眠の質改善剤。
〔5〕セイヨウトネリコエキスが、セイヨウトネリコの種子の抽出エキスである前記〔4〕に記載の睡眠の質改善剤。
〔6〕シベリアカラマツエキスを有効成分とする前記〔1〕に記載の睡眠の質改善剤。
〔7〕ジヒドロケルセチン、ジヒドロケンフェロールおよびナリンゲニンからなる群より選ばれる1または2以上の化合物を有効成分とする前記〔1〕に記載の睡眠の質改善剤。
〔8〕入眠潜時を短縮する前記〔1〕〜〔7〕のいずれか一項に記載の睡眠の質改善剤。
〔9〕睡眠初期のノンレム睡眠を深くする前記〔1〕〜〔8〕のいずれか一項に記載の睡眠の質改善剤。
〔10〕睡眠時間全体に占めるノンレム睡眠時間の割合を増加する前記〔1〕〜〔9〕のいずれか一項に記載の睡眠の質改善剤。
〔11〕起床時の眠気のなさを改善する前記〔1〕〜〔10〕のいずれか一項に記載の睡眠の質改善剤。
〔12〕寝つきと熟眠感を改善する前記〔1〕〜〔11〕のいずれか一項に記載の睡眠の質改善剤。
〔13〕夢見を改善する前記〔1〕〜〔12〕のいずれか一項に記載の睡眠の質改善剤。
〔14〕疲労感を改善する前記〔1〕〜〔13〕のいずれか一項に記載の睡眠の質改善剤。
〔15〕睡眠時間の満足感を改善する前記〔1〕〜〔14〕のいずれか一項に記載の睡眠の質改善剤。
〔16〕前記〔1〕〜〔15〕のいずれか一項に記載の睡眠の質改善剤を含有する睡眠の質改善組成物。
〔17〕トネリコ属植物またはその抽出エキスを睡眠の質改善のために使用する方法。
〔18〕シベリアカラマツエキスを睡眠の質改善のために使用する方法。
〔19〕ジヒドロケルセチン、ジヒドロケンフェロールおよびナリンゲニンからなる群より選ばれる1または2以上の化合物を睡眠の質改善のために使用する方法。
〔1−1〕トネリコ属植物またはその抽出エキスを有効成分とする睡眠の質改善剤。
〔1−2〕トネリコ属植物がセイヨウトネリコである上記〔1−1〕に記載の睡眠の質改善剤。
〔1−3〕トネリコ属植物の抽出エキスがセイヨウトネリコエキスである上記〔1−1〕に記載の睡眠の質改善剤。
〔1−4〕入眠潜時を短縮する上記〔1−1〕〜〔1−3〕のいずれか一項に記載の睡眠の質改善剤。
〔1−5〕睡眠初期のノンレム睡眠を深くする上記〔1−1〕〜〔1−4〕のいずれか一項に記載の睡眠の質改善剤。
〔1−6〕睡眠時間全体に占めるノンレム睡眠時間の割合を増加する上記〔1−1〕〜〔1−5〕のいずれか一項に記載の睡眠の質改善剤。
〔1−7〕起床時の眠気のなさを改善する上記〔1−1〕〜〔1−6〕のいずれか一項に記載の睡眠の質改善剤。
〔1−8〕寝つきと熟眠感を改善する上記〔1−1〕〜〔1−7〕のいずれか一項に記載の睡眠の質改善剤。
〔1−9〕夢見を改善する上記〔1−1〕〜〔1−8〕のいずれか一項に記載の睡眠の質改善剤。
〔1−10〕疲労感を改善する上記〔1−1〕〜〔1−9〕のいずれか一項に記載の睡眠の質改善剤。
〔1−11〕睡眠時間の満足感を改善する上記〔1−1〕〜〔1−10〕のいずれか一項に記載の睡眠の質改善剤。
〔1−12〕セイヨウトネリコエキスが、セイヨウトネリコの種子の抽出エキスである上記〔1−1〕〜〔1−11〕のいずれか一項に記載の睡眠の質改善剤。
〔1−13〕上記〔1−1〕〜〔1−12〕のいずれか一項に記載の睡眠の質改善剤を含有する睡眠の質改善組成物。
〔1−14〕トネリコ属植物またはその抽出エキスを睡眠の質改善のために使用する方法。
〔2−1〕シベリアカラマツエキスを有効成分とする睡眠の質改善剤。
〔2−2〕ジヒドロケルセチン、ジヒドロケンフェロールおよびナリンゲニンからなる群より選ばれる1または2以上の化合物を有効成分とする睡眠の質改善剤。
〔2−3〕起床時の眠気のなさを改善する上記〔2−1〕または〔2−2〕に記載の睡眠の質改善剤。
〔2−4〕寝つきと熟眠感を改善する上記〔2−1〕〜〔2−3〕のいずれか一項に記載の睡眠の質改善剤。
〔2−5〕夢見を改善する上記〔2−1〕〜〔2−4〕のいずれか一項に記載の睡眠の質改善剤。
〔2−6〕疲労感を改善する上記〔2−1〕〜〔2−5〕のいずれか一項に記載の睡眠の質改善剤。
〔2−7〕睡眠時間の満足感を改善する上記〔2−1〕〜〔2−6〕のいずれか一項に記載の睡眠の質改善剤。
〔2−8〕上記〔2−1〕〜〔2−7〕のいずれか一項に記載の睡眠の質改善剤を含有する睡眠の質改善組成物。
〔2−9〕シベリアカラマツエキスを睡眠の質改善のために使用する方法。
〔2−10〕ジヒドロケルセチン、ジヒドロケンフェロールおよびナリンゲニンからなる群より選ばれる1または2以上の化合物を睡眠の質改善のために使用する方法。
トネリコ属植物の抽出エキスの睡眠誘発効果を確認するために、表1に示す各サンプルを用いて以下の試験を行った。
セイヨウトネリコエキスが睡眠の質に与える効果を確認するために、以下の試験を行い脳波を測定した。すなわち、マウス頭部に電極を装着し、記録用チャンバー内において自由行動下のマウス脳波を記録し、「覚醒」「レム睡眠」「ノンレム睡眠」の各時間を測定した。
セイヨウトネリコエキスがヒトの睡眠の質に与える効果を確認するために、表3に示す各サンプルを用いて以下の試験を行った。
脳波はスリープウェル(株)に依頼して解析した。就寝(脳波測定開始)からノンレム睡眠出現までの時間を入眠潜時とした。睡眠の深さは睡眠中脳波のデルタ波パワー値によって知ることができ、デルタ波パワー値が大きいほど睡眠の深さは深い。就寝直後にノンレム睡眠が出現し、その後レム睡眠が出現する。レム睡眠が出現するまでの就寝直後のノンレム睡眠中のデルタ波パワー値を、睡眠初期のデルタ波パワー値とした。
入眠潜時の変化率(%)=
{(セイヨウトネリコエキス摂取後の入眠潜時の平均値)/(プラセボ摂取後の入眠潜時の値の平均値)}×100−100
デルタ波パワー値の変化率(%)=
{(セイヨウトネリコエキス摂取後のデルタ波パワー値の平均値)/(プラセボ摂取後のデルタ波パワー値の平均値)}×100−100
睡眠感の調査には、OSA睡眠調査票MA版(山本由華吏,田中秀樹,高瀬美紀,山崎勝男,阿住一雄,白川修一郎:中高年・高齢者を対象としたOSA睡眠調査票(MA版)の開発と標準化.脳と精神の医学 10:401−409,1999.)を用いた。OSA睡眠調査票MA版は、20項目の質問から構成されており、因子I:起床時眠気(すなわち起床時の眠気のなさ)、因子II:入眠と睡眠維持(すなわち良い寝つきと熟眠感のよさ)、因子III:夢見(すなわち夢見のよさ)、因子IV:疲労回復(すなわち疲労感のなさ)、因子V:睡眠時間(すなわち睡眠時間の満足感)を評価するための評価法である。
各因子の点数の変化率(%)=
{(セイヨウトネリコエキス含有酵母摂取後の値の平均値)/(プラセボ摂取後の値の平均値)}×100−100
疲労感の調査には、日本疲労学会が特定保健用食品の抗疲労臨床評価における疲労感の評価方法のガイドラインに示している日本疲労学会推奨のVisual Analogue Scale(VAS)検査用紙を用いた。すなわち、一定の長さの水平な直線の左端を「疲れをまったく感じない最良の感覚」、右端を「何もできないほど疲れきった最悪の感覚」とし、パネラーが朝起きたときの感覚を、直線の左右両端に示した感覚を参考にこの直線上に×印で回答した。
疲労感の変化率(%)={(セイヨウトネリコエキス摂取後の値の平均値)/(プラセボ摂取後の値の平均値)}×100−100
セイヨウトネリコエキス10mg、乳糖60mg、結晶セルロース80mg、カルボキシメチルセルロース−Ca5mg、ショ糖脂肪酸エステル5mgを常法どおり打錠し錠剤を製造した。
セイヨウトネリコエキス250mg、結晶セルロース40mg、カルボキシメチルセルロース−Ca5mg、ショ糖脂肪酸エステル5mgを常法どおり打錠し錠剤を製造した。
以下の原料を用いて、常法により錠剤を製造した。
以下の原料を用いて、常法によりソフトカプセルを製造した。
シベリアカラマツエキスおよびジヒドロケルセチンの睡眠誘発効果を確認するために、表7及び表8に示す各サンプルを用いて以下の試験を行った。
シベリアカラマツエキスがヒトの睡眠の質に与える効果を確認するために、表9に示す各サンプルを用いて以下の試験を行った。
各因子の点数の変化率(%)=
{(シベリアカラマツエキス含有酵母摂取後の値の平均値)/(プラセボ摂取後の値の平均値)}×100−100
シベリアカラマツエキス10mg、乳糖60mg、結晶セルロース80mg、カルボキシメチルセルロース−Ca5mg、ショ糖脂肪酸エステル5mgを常法どおり打錠し錠剤を製造した。
以下の原料を用いて、常法により錠剤を製造した。
以下の原料を用いて、常法によりソフトカプセルを製造した。
Claims (12)
- セイヨウトネリコ、セイヨウトネリコエキスおよびシベリアカラマツエキスからなる群より選ばれる1または2以上を有効成分とする睡眠の質改善剤。
- セイヨウトネリコエキスが、セイヨウトネリコの種子の抽出エキスである請求項1に記載の睡眠の質改善剤。
- シベリアカラマツエキスを有効成分とする請求項1または2に記載の睡眠の質改善剤。
- 入眠潜時を短縮する請求項1〜3のいずれか一項に記載の睡眠の質改善剤。
- 睡眠初期のノンレム睡眠を深くする請求項1〜4のいずれか一項に記載の睡眠の質改善剤。
- 睡眠時間全体に占めるノンレム睡眠時間の割合を増加する請求項1〜5のいずれか一項に記載の睡眠の質改善剤。
- 起床時の眠気のなさを改善する請求項1〜6のいずれか一項に記載の睡眠の質改善剤。
- 寝つきと熟眠感を改善する請求項1〜7のいずれか一項に記載の睡眠の質改善剤。
- 夢見を改善する請求項1〜8のいずれか一項に記載の睡眠の質改善剤。
- 疲労感を改善する請求項1〜9のいずれか一項に記載の睡眠の質改善剤。
- 睡眠時間の満足感を改善する請求項1〜10のいずれか一項に記載の睡眠の質改善剤。
- 請求項1〜11のいずれか一項に記載の睡眠の質改善剤を含有する睡眠の質改善組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011222256 | 2011-10-06 | ||
JP2011222255 | 2011-10-06 | ||
JP2011222256 | 2011-10-06 | ||
JP2011222255 | 2011-10-06 | ||
PCT/JP2012/076088 WO2013051727A1 (ja) | 2011-10-06 | 2012-10-09 | 睡眠の質改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013051727A1 JPWO2013051727A1 (ja) | 2015-03-30 |
JP6100692B2 true JP6100692B2 (ja) | 2017-03-22 |
Family
ID=48043880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537583A Active JP6100692B2 (ja) | 2011-10-06 | 2012-10-09 | 睡眠の質改善剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140248383A1 (ja) |
JP (1) | JP6100692B2 (ja) |
KR (2) | KR20190055258A (ja) |
CN (2) | CN103857404A (ja) |
WO (1) | WO2013051727A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105614604A (zh) * | 2015-12-22 | 2016-06-01 | 内蒙古满洲里森诺生物科技有限公司 | 落叶松树皮提取物饮料及其制备方法 |
US11324784B2 (en) | 2018-03-28 | 2022-05-10 | Morinaga Milk Industry Co., Ltd. | Sleep-promoting composition, and medical composition and food beverage composition using said sleep-promoting composition |
JP7279085B2 (ja) | 2018-06-26 | 2023-05-22 | ランダ コーポレイション リミテッド | デジタル印刷システム用の中間転写部材 |
US20210161190A1 (en) * | 2018-08-21 | 2021-06-03 | Japan Tobacco Inc. | Core body temperature reducing agent, food product, and sleep improving agent |
KR102170418B1 (ko) * | 2018-10-17 | 2020-10-27 | 한국 한의학 연구원 | 프락시누스속 식물 추출물을 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물 |
US11507169B2 (en) * | 2019-04-04 | 2022-11-22 | Motorola Mobility Llc | User state-based device power conservation |
US11166128B2 (en) | 2019-04-04 | 2021-11-02 | Motorola Mobility Llc | User state-based handling of calls and alerts |
CN118338792A (zh) | 2021-12-15 | 2024-07-12 | 大塚制药株式会社 | 睡眠质量改善或自主神经调节用组合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE477809T1 (de) | 2004-04-06 | 2010-09-15 | Taiyokagaku Co Ltd | Verwendung einer kombination von theanin und serotonin gegen schlafstörung |
WO2005115547A2 (en) * | 2004-05-18 | 2005-12-08 | Bright Future Pharmaceutical Laboratories Ltd. | Myricitrin compounds for sleeping disorders |
JP2006028051A (ja) | 2004-07-14 | 2006-02-02 | Lion Corp | 起床時疲労感改善剤、起床時疲労感改善用組成物、及びこれらを含む起床時疲労感改善用飲食物 |
JP4874532B2 (ja) | 2004-08-25 | 2012-02-15 | 株式会社琉球バイオリソース開発 | 睡眠改善剤 |
JP5414192B2 (ja) * | 2007-03-29 | 2014-02-12 | 江崎グリコ株式会社 | 概日リズム調整組成物 |
WO2008146883A1 (ja) * | 2007-05-29 | 2008-12-04 | Osaka Bioscience Institute | 睡眠改善剤 |
US8142826B2 (en) * | 2007-11-05 | 2012-03-27 | Naturex, Inc. | Extract of Fraxinus excelsior seeds and therapeutic applications therefor |
JP2010064992A (ja) * | 2008-09-11 | 2010-03-25 | Hayashibara Biochem Lab Inc | ペルオキシソーム増殖剤応答性核内受容体α活性化剤 |
-
2012
- 2012-10-09 KR KR1020197013477A patent/KR20190055258A/ko not_active Application Discontinuation
- 2012-10-09 CN CN201280048797.1A patent/CN103857404A/zh active Pending
- 2012-10-09 WO PCT/JP2012/076088 patent/WO2013051727A1/ja active Application Filing
- 2012-10-09 CN CN201710474042.2A patent/CN107496469A/zh active Pending
- 2012-10-09 JP JP2013537583A patent/JP6100692B2/ja active Active
- 2012-10-09 KR KR1020147007817A patent/KR20140082666A/ko not_active Application Discontinuation
- 2012-10-09 US US14/349,214 patent/US20140248383A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2013051727A1 (ja) | 2013-04-11 |
CN107496469A (zh) | 2017-12-22 |
JPWO2013051727A1 (ja) | 2015-03-30 |
CN103857404A (zh) | 2014-06-11 |
KR20140082666A (ko) | 2014-07-02 |
KR20190055258A (ko) | 2019-05-22 |
US20140248383A1 (en) | 2014-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6100692B2 (ja) | 睡眠の質改善剤 | |
WO2013051728A1 (ja) | 睡眠の質改善剤 | |
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
WO2014017243A1 (ja) | 睡眠の質改善剤 | |
US11596664B2 (en) | Plant extracts made of Sideritis and use thereof to boost cognitive performance | |
JPH0832631B2 (ja) | 精神安定用飲食物 | |
CN102919496A (zh) | 一种无糖保健口香糖 | |
JP6864964B2 (ja) | 経口睡眠改善剤 | |
KR102262763B1 (ko) | 강황 복합 추출물을 유효성분으로 함유하는 수면 장애의 예방, 개선 또는 치료용 조성물 | |
JPH1025246A (ja) | 催眠剤、催眠性飲食物及び催眠性餌料 | |
CN115768417A (zh) | 肌肉萎缩抑制剂 | |
JP4669077B1 (ja) | アスパラガス擬葉を有効成分とする自律神経調整剤 | |
KR101720681B1 (ko) | 호프 추출물을 포함하는 수면 촉진용 조성물 | |
WO2021106857A1 (ja) | 尿意ストレス予防または緩和用組成物及び睡眠改善用組成物 | |
TWI803146B (zh) | 龍眼花萃取物提升體內褪黑激素的用途 | |
WO2020040216A1 (ja) | 深部体温低下剤、食品、睡眠改善剤 | |
KR101735275B1 (ko) | 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물 | |
JP2023070130A (ja) | 睡眠の質の改善剤 | |
KR20220059650A (ko) | 얼레지 추출물을 유효성분으로 함유하는 우울 증상, 스트레스 또는 인지기능 장애의 개선, 예방 또는 치료용 조성물 | |
CN115023234A (zh) | 睡眠质量提升用组合物 | |
KR20210048744A (ko) | 고구마 줄기 추출물을 유효성분으로 포함하는 이명의 예방 또는 치료용 조성물 | |
WO2014163152A1 (ja) | ノンレム睡眠促進剤、深睡眠促進剤および自然睡眠誘発剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6100692 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |